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Abstract: Heart failure (HF) is a complex clinical syndrome that can result from any structural or functional cardiac 
disorder that impairs the ability of the ventricle to fill with or eject blood. Due to the aging of the population it has become 
a growing public health problem in recent decades. Diagnosis of HF is clinical and there is no diagnostic test, although 
some basic complementary testing should be performed in all patients. Depending on the ejection fraction (EF), the 
syndrome is classified as HF with low EF or HF with normal EF (HFNEF). Although prognosis in HF is poor, HFNEF 
seems to be more benign. HF and ischemic stroke (IS) share vascular risk factors such as age, hypertension, diabetes 
mellitus, coronary artery disease and atrial fibrillation. Persons with HF have higher incidence of IS, varying from 1.7% to 
10.4% per year across various cohort studies. The stroke rate increases with length of follow-up. Reduced EF, 
independent of severity, is associated with higher risk of stroke. Left ventricular mass and geometry are also related with 
stroke incidence, with concentric hypertrophy carrying the greatest risk.  
In HF with low EF, the stroke mechanism may be embolism, cerebral hypoperfusion or both, whereas in HFNEF the 
mechanism is more typically associated with chronic endothelial damage of the small vessels. Stroke in patients with HF 
is more severe and is associated with a higher rate of recurrence, dependency, and short term and long term mortality. 
Cardiac morbidity and mortality is also high in these patients. Acute stroke treatment in HF includes all the current 
therapeutic options to more carefully control blood pressure. For secondary prevention, optimal control of all vascular risk 
factors is essential. Antithrombotic therapy is mandatory, although the choice of a platelet inhibitor or anticoagulant drug 
depends on the cardiac disease. Trials are ongoing to evaluate anticoagulant therapy for prevention of embolism in 
patients with low EF who are at sinus rhythm.  
Keywords: Heart failure, stroke, outcome. 
INTRODUCTION 
  Heart failure (HF) is a major and growing public health 
problem in the United States, with approximately 5 million 
cases and over 550 000 patients diagnosed with HF for the 
first time each year [1]. HF is primarily a condition of the 
elderly, and thus the widely recognized “aging of the popu-
lation” also contributes to its increasing incidence. Although 
patients with HF face a high risk of mortality and cardiovas-
cular morbidity, survival has improved in recent years with 
better therapeutic strategies. Hospital discharges for HF rose 
from 877 000 in 1996 to 1 106 000 in 2006 [2] and the total 
estimated direct and indirect costs for HF have also increa-
sed, from $27.9 billion in 2005 to $39.2 billion in 2010 [3]. 
  HF and ischemic stroke (IS) share similar risk factors and 
HF itself is a risk factor for IS. Moreover, IS in patients with 
HF is more severe and has a poor prognosis. The aim of this 
chapter is to review the main causes of HF, the risk of stroke 
in patients with HF, and the treatment and prognosis of HF 
in IS.  
THE NATURAL HISTORY OF HEART FAILURE 
  Heart failure (HF) is a complex clinical syndrome that 
can result from any structural or functional cardiac disorder  
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that impairs the ability of the ventricle to fill with or eject 
blood. HF is characterized by specific symptoms (dyspnea 
and fatigue) in the medical history and signs (edema, rales) 
during physical examination.  
  The clinical syndrome of HF may result from disorders 
of the pericardium, myocardium, endocardium, or great 
vessels, but the majority of patients with HF have symptoms 
due to an impairment of left ventricle (LV) myocardial 
function. Coronary artery disease (CAD), hypertension, 
valvular disease and dilated cardiomyopathy are the main 
causes of HF in the western world [4]. Cardiomyopathies 
(CM) are a heterogeneous group of diseases of the 
myocardium associated with mechanical and/or electrical 
dysfunction; there is a variety of causes, frequently genetic. 
Inappropriate ventricular hypertrophy or dilatation is usually 
exhibited [5,6].  
  The classification system most commonly used to 
quantify the degree of functional limitation was developed 
by the New York Heart Association (NYHA). This system 
assigns patients to a functional class based on the degree of 
effort needed to elicit symptoms: Class I- symptoms of HF 
only at activity levels that would limit normal individuals; 
Class II- symptoms of HF with ordinary exertion; Class III- 
symptoms of HF with less than ordinary exertion; and Class 
IV- symptoms of HF at rest.  
  However, there is a poor relationship between measures 
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disease. Patients with a very low EF may be asymptomatic, 
whereas patients with preserved LVEF may have severe 
disability. In fact, it is estimated that although 2.9% of the 
USA population has an EF30%, only half of these 
individuals have symptomatic HF [7].  
  HF is a progressive disorder. Its development has been 
characterized by 4 stages: Stage A- High risk for HF without 
structural heart disease or symptoms; Stage B- Heart disease 
with asymptomatic LV dysfunction; Stage C- Prior or 
current symptoms of HF; Stage D- Refractory end stage HF. 
In contrast to NYHA classification, this staging system 
emphasizes the progressive nature of HF and defines the 
appropriate therapeutic approach for each stage.  
  The principal manifestation of the progression is a 
change in the geometry and structure of the LV, such that the 
chamber dilates and/or hypertrophies and becomes more 
spherical—a process referred to as cardiac remodeling. 
Cardiac remodeling generally precedes the development of 
symptoms (occasionally by months or even years), continues 
after the appearance of symptoms, and contributes substan-
tially to worsening of symptoms despite treatment. The 
activation of endogenous neurohormonal systems plays an 
important role in cardiac remodeling and thereby in the 
progression of HF.  
  Patients with HF have elevated circulating or tissue 
levels of norepinephrine, angiotensin II, aldosterone, endo-
thelin, vasopressin, and cytokines, which can act (alone or in 
concert) to adversely affect the structure and function of the 
heart. These neurohormonal factors not only increase the 
hemodynamic stresses on the ventricle by causing sodium 
retention and peripheral vasoconstriction but may also exert 
direct toxic effects on cardiac cells. 
  Heart failure has been traditionally classified as “dias-
tolic” (preserved EF) or “systolic” (reduced EF). However, 
this nomenclature has become the subject of controversy  [8] 
and some have suggested that the phenotypic expression of 
HF occurs on a continuum, with underlying myocardial 
dysfunction present in the early stages of the syndrome when 
diastolic abnormalities predominate  [9]. Since 2005 the 
American College of Cardiology-American Heart Asso-
ciation (ACC/AHA) guidelines for the diagnosis and 
management of heart failure have used the term “heart 
failure with preserved or normal ejection fraction” (HFNEF) 
rather than “diastolic heart failure”  [1]. Depending on the 
criteria used to delineate HF and the accepted cutoff for 
defining preserved LVEF, it is estimated that as many as 
20% to 60% of patients with HF have a relatively normal 
LVEF and, in the absence of valvular disease, are believed to 
have reduced ventricular compliance as a major contributor 
to the clinical syndrome  [10,11]. In HFNEF, clinical presen-
tation can be as dramatic as that in patients with low LVEF, 
for example in patients admitted with acute pulmonary 
edema  [12]. 
  In general, a definitive diagnosis of HFNEF can be made 
when the rate of ventricular relaxation is slowed according to 
some diagnostic criteria  [13]. In practice, the diagnosis is 
generally based on the finding of typical symptoms and signs 
of HF in a patient who is shown to have a normal LVEF and 
no valvular abnormalities (aortic stenosis or mitral 
regurgitation, for example) on echocardiography.  
  In the Acute Decompensated Heart Failure National 
Registry (ADHERE) database  [14], among 52 187 patients 
admitted to hospital for acute decompensated HF, patients 
with HFNEF (n = 26 322) were more likely to be older and 
female, and less likely to have CAD or a previous 
myocardial infarction. The HFNEF group was more likely to 
have comorbidities such as hypertension and diabetes than 
patients with HF and low EF. Atrial fibrillation (AF) and 
obesity have also been associated with HFNEF more 
frequently than HF with low EF  [10,15].  
  HF is the end stage of a cardiac disease and therefore 
prognosis is poor. The 1-year mortality rate for HF is high 
(20%) and 5-year survival is lower in men than in women: 
59% of men and 45% of women will die within 5 years of 
HF diagnosis  [3]. 
  The ADHERE registry  [14] also revealed a lower overall 
mortality in HFNEF patients compared with low EF patients, 
whereas symptom burden, duration of intensive care unit 
stay, overall length of hospital stay, and long-term mortality 
were similar between the two groups. 
  Most, but not all, series of patients with HFNEF have 
shown better survival than is seen in patients with HF and 
reduced LVEF  [10,11,16]. Moreover, secular trends have 
revealed slightly improved survival in patients with HF and 
low EF over the past 20 years, attributed to recent thera-
peutic advances in the treatment of systolic HF. Never-
theless, death rates from HFNEF remained unchanged.   
[10,11,16] These studies highlight a change in HF epide-
miology, with HFNEF prevalence increasing along with 
increasing age of the population, and the inadequacy of 
current therapeutic options for this disease. 
DIAGNOSIS  
  There are many ways to assess cardiac function. How-
ever, there is no diagnostic test for HF, since it is largely a 
clinical diagnosis based upon a physical examination and 
careful attention to the patient’s medical history. Recom-
mendations for the evaluation of patients with HF are sum-
marized in Table I. A complete history, including assessment 
of NYHA functional class, and physical examination are the 
first steps in evaluating the cause of HF and its severity. 
Direct inquiry may reveal prior or current evidence of MI, 
valvular disease or congenital heart disease, whereas 
examination of the heart may suggest the presence of cardiac 
enlargement, murmurs or a third heart sound.  
  All patients with HF should have a 12-lead electro-
cardiogram (EKG), chest x-ray and complete laboratory ana-
lysis (blood count, urinalysis, serum electrolytes, glyco-
hemoglobin, and blood lipids), as well as tests of renal, 
hepatic and thyroid function. Additional tests may be 
warranted to establish the etiology. 
  Measurement of natriuretic peptides (BNP, pro-BNP) in 
the emergency room helps to differentiate dyspnea due to HF 
from dyspnea due to other causes and reduces the length of 
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The single most useful diagnostic test in the evaluation of 
patients with HF is the 2-dimensional echocardiogram 
coupled with Doppler flow studies. Echocardiography has a 
high sensitivity and specificity for the diagnosis of myocar-
dial dysfunction, and may also establish the etiology of HF  
[18]. Other tests such as radionuclide ventriculography, mag-
netic resonance imaging or computed tomography might be 
useful in selected cases.  
  Given that CAD is believed to be the underlying cause of 
HF with low EF in two-thirds of patients, all patients with 
unexplained HF should be evaluated for the presence of 
Table I.  Recommendations for the Evaluation of Patients with HF Included in the  2005 ACC/AHA Guidelines with  2009 Focused 
Update (1) 
Class I - There is Evidence and/or General Agreement that the Initial Evaluation of Patients Presenting with HF Should Include the Following: 
A complete history and physical examination to identify cardiac and non cardiac disorders or behaviors that might cause or accelerate the development or 
progression of HF. 
A careful history of current and past use of alcohol, illicit drugs, standard or "alternative" therapies, and chemotherapy drugs. 
An assessment of the ability to perform routine and desired activities of daily living. 
An assessment of the volume status, orthostatic blood pressure changes, height and weight, and calculation of body mass index. 
Laboratory studies including complete blood count, urinalysis, serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum 
creatinine, fasting blood glucose (glycohemoglobin), lipid profile, liver function tests, and serum thyroid-stimulating hormone. 
A 12-lead electrocardiogram and chest radiograph (posteroanterior and lateral). 
Two-dimensional echocardiography with Doppler to assess left ventricular ejection fraction (LVEF), left ventricular size, wall thickness, and valve 
function. Radionuclide ventriculography can be performed to assess LVEF and volumes. 
Coronary arteriography if there is a history of angina or significant ischemia unless the patient is not eligible for revascularization of any kind. 
Class IIa - The Weight of Evidence or Opinion is in Favor of Benefit From Performing the Following Studies as Part of the Initial Evaluation of 
Patients Presenting with HF: 
Coronary arteriography in patients who have chest pain that may or may not be of cardiac origin who have not had a prior evaluation of their coronary 
anatomy and are eligible for coronary revascularization. 
Coronary arteriography in patients with known or suspected coronary artery disease who do not have angina and are eligible for revascularization. 
Noninvasive imaging to detect myocardial ischemia and viability in patients with known or suspected coronary artery who do not have angina and are 
eligible for revascularization. 
When the contribution of HF to exercise limitation is uncertain, maximal exercise testing with or without measurement of respiratory gas exchange and/or 
blood oxygen saturation. 
To identify candidates for cardiac transplantation or other advanced treatments, maximal exercise testing with measurement of respiratory gas exchange. 
In selected patients, screening for hemochromatosis, sleep disturbed breathing, or human immunodeficiency virus (HIV) infection. 
When suspected clinically, diagnostic tests for rheumatologic disease, amyloidosis, or pheochromocytoma. 
Endomyocardial biopsy when a specific diagnosis is suspected that would influence therapy. 
Measurement of serum B-type natriuretic peptide (BNP) in the urgent care setting if the clinical diagnosis of HF is uncertain. Measurement of natriuretic 
peptides (BNP and NT-proBNP) can be useful in risk stratification. 
Class IIb - The Weight of Evidence or Opinion is Less Well Established for the Following Testing in the Initial Evaluation of Patients with HF 
Noninvasive imaging to define the likelihood of coronary artery disease in patients with left ventricular dysfunction. 
Holter monitoring in patients who have a history of myocardial infarction and are being considered for electrophysiologic study to document the 
inducibility of ventricular tachycardia. 
Class III - There is Evidence and/or General Agreement that the Following Tests are not Useful or may be Harmful in the Initial Evaluation of 
Patients with HF 
Routine endomyocardial biopsy in the absence of suspicion of a specific diagnosis that would influence therapy suspected. 
Routine signal-averaged electrocardiography. 
Routine measurement of serum neurohormones other than BNP (eg, norepinephrine or endothelin). Heart Failure in Acute Ischemic Stroke  Current Cardiology Reviews, 2010, Vol. 6, No. 3    205 
CAD. The noninvasive exercise test is a reasonable first step. 
In addition to detection of ischemic heart disease, exercise 
capacity can be used for risk stratification and determining 
prognosis as well as assessing the efficacy of therapy in 
patients over time. Coronary catheterization with angio-
graphy should be considered in patients with angina or a 
positive exercise test. 
  Angiography shows normal or near-normal coronary 
arteries in half of the patients with HF and low EF  [1]; most 
of these patients could have a myocardial disorder. MRI may 
be helpful in distinguishing IHD from CM and identifying 
the type. Endomyocardial biopsy and genetic evaluation 
should be reserved for patients with established indications. 
HF AND THE RISK OF ISCHEMIC STROKE 
  The risk of stroke in patients with HF has been related to 
the coexistence of vascular risk factors, the EF and left 
ventricle geometry. Although hypertension is the strongest 
risk factor for stroke, epidemiological studies have found 
increased risk of stroke associated with other risk factors, 
including cardiovascular abnormalities such as CAD, HF and 
atrial fibrillation (AF)  [19]. In the Framingham study, the 
age-adjusted 2-year incidence of stroke was more than 
double in the presence of CAD, more than triple in the 
presence of hypertension, more than quadruple in the pre-
sence of HF and nearly quintupled when AF was present   
[19].  
  AF and HF often coexist in the same patient. AF is 
present in 10–50% of patients with HF, with the highest 
incidence in those with NYHA functional class IV; HF itself 
is also an independent predictor of AF  [20]. In a meta-
analysis of independent risk factors for stroke in patients 
with AF, the associated variables were prior stroke/TIA (RR: 
2.5), increasing age (RR: 1.5 per decade), history of hyper-
tension (RR: 2.0) and diabetes mellitus (RR: 1.7). Clinical 
HF was not consistently an independent predictor in AF 
patients; some studies found an association in patients with 
low EF that has not been confirmed in other studies  [21]. 
  Vascular risk factors (VRF) that increase the risk of 
stroke in AF (prior stroke, age, hypertension and diabetes) 
appear to also increase the stroke risk in HF, but the 
published findings are inconsistent. Age, prior stroke and 
diabetes were found to be risk factors in a community based 
study that compared stroke risk in 630 HF patients with the 
general population  [22]. However, the Studies of Left 
Ventricular Dysfunction (SOLVD), which included 6738 
patients with symptomatic or asymptomatic HF, found that 
age, hypertension and prior stroke were risk factors only in 
men. In women, diabetes and smoking were the only VRF.  
[23] Other retrospective studies have found only age  [24] or 
hypertension  [25] to be significant VRF of stroke in patients 
with HF.  
  Persons with HF have higher incidence of strokes; 
nevertheless, there is marked variability in the stroke rates 
reported in different studies. As would be expected, the 
stroke rate in unselected cohorts of persons with HF is 
slightly higher than in clinical trials. Indeed, stroke rate 
varies from 1.7% to 10.4% in cohort studies  [26-28] com-
pared with 0.6% to 4% in HF clinical trials  [23,24,29-31]. 
The heterogeneity in study design and follow-up periods 
makes it difficult to generalize these findings to clinical 
practice. A recent meta-analysis of 26 population studies of 
chronic HF with IS during follow-up, irrespective of EF or 
heart rhythm, found a stroke rate (95%CI) of 18.4 [16.9-
19.9) per 1000 cases during the first year of HF. This rate 
tended to increase with duration of follow-up, to a maximum 
of 47.4 [45.6-49.2) strokes per 1000 cases at 5 years. In this 
meta-analysis, studies with a higher proportion of men, those 
conducted in 1990 or earlier, and cohort studies reported 
higher stroke rates than studies with more women, those 
conducted after 1990 and clinical trials  [32]. 
  In community studies, the prevalence of stroke/TIA is 
higher in individuals with HF than in the general population. 
In the Framingham study, the adjusted risk of stroke 
associated with HF was 4.3 at 2 years follow-up  [19]. In a 
study in Olmsted County, the stroke risk among those with 
HF was 2.9 times the control population risk over 5 years  
[22]. In the Reasons for Geographic And Racial Differences 
in Stroke (REGARDS), a U.S. population study that has 
included more than 30 000 participants, the prevalence of 
self-reported history of stroke or TIA was analyzed for HF, 
defined by the use of digoxin. The adjusted OR for the 
association between HF and stroke/TIA was 3.0 (95% CI: 
2.2-4.0) [33]. 
  Reduced EF (symptomatic or asymptomatic) has been 
found to be a risk factor for stroke, most often in prospective 
studies of MI survivors. In general, the stroke rate is relati-
vely low, ranging from 1.3% to 3.5% per year. However, 
stroke was not the primary endpoint and these studies might 
have underestimated the occurrence [34] Survival and 
Ventricular Enlargement (SAVE) was a prospective trial 
with 5 years follow-up that assessed the relation between 
LVEF and the incidence of stroke in 2231 patients with LV 
dysfunction after acute MI but without symptomatic HF   
[24]. LVEF was found to be an independent risk factor. For 
every 5% decrease in EF there was an 18% increase in the 
risk of stroke. In addition, patients with EF lower than 28% 
had a relative risk of stroke of 1.86, compared with patients 
with higher LVEF. Moreover, retrospective analysis of 
SOLVD data found a 58% increase in risk of thrombo-
embolic events for every 10% decrease in EF among women. 
There was no significant increase in stroke risk among men 
in that trial  [23]. Low EF was a risk factor for stroke in the 
multiethnic North Manhattan (NOMASS) population cohort, 
independently of age, sex and ethnicity; however, risk of 
stroke was not related to severity of EF reduction [35].  
  The TOAST (Trial of Org 10172 in Acute Stroke Treat-
ment) classification [36], the most widely accepted 
etiological classification of ischemic strokes, was actualized 
in 2005 by the Stop Stroke Study TOAST (SSS-TOAST) 
system [37]. Due to new epidemiological evidence, sympto-
matic HF with low EF and chronic myocardial infarction 
(MI) with EF less than 28% were included as primary high 
risk sources of embolic stroke. Recent MI (< 4 weeks) and 
dilated CM were in the high risk category in the original 
classification and were maintained in the new system. All 
sources of cardiac embolism considered in this classification 
are listed in Table II. High risk cardiac sources have greater  
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Table  II.  Cardioaortic Sources of Cerebral Embolism 
According to the SSS TOAST Classification [37] 
Sources with High Primary Risk for Ischemic Stroke 
Sources of embolism of thrombotic origin 
-Left atrial thrombus 
-Left ventricular thrombus 
-Atrial fibrillation 
-Paroxysmal atrial fibrillation 
-Sick sinus syndrome 
-Sustained atrial flutter 
-Recent myocardial infarction (within 1 month) 
-Rheumatoid mitral or aortic valve disease 
-Bioprosthetic and mechanical heart valves 
-Chronic myocardial infarction together with low ejection fraction less 
than 28% 
-Symptomatic congestive heart failure with ejection fraction less than 
30% 
-Dilated cardiomyopathy 
-Nonbacterial thrombotic endocarditis 
Sources with embolism not predominantly of thrombotic origin 
-Infective endocarditis 
-Papillary fibroelastoma 
-Left atrial myxoma 
Sources with Low or Uncertain Primary Risk for Ischemic Stroke 
Cardiac sources of embolism 
-Mitral annular calcification 
-Patent foramen ovale 
-Atrial septal aneurysm 
-Atrial septal aneurysm and patent foramen ovale 
-Left ventricular aneurysm without thrombus 
-Isolated left atrial smoke (no mitral stenosis or atrial fibrillation) 
Aortic sources of embolism 
-Complex atheroma in the ascending aorta or proximal arch 
 
than 2% annual primary risk for stroke. The low-risk group 
includes cardiac sources with less than 2% primary risk for 
stroke, yet some cardiac abnormalities associated with 
increased risk for recurrent stroke but undetermined risk for 
first-ever stroke were also included in this category. 
  In patients with non-ischemic dilated CM, the rate of 
stroke appears similar to that in patients with CM due to 
CAD. Again there is high variability across studies and most 
of the studies included small series of patients  [38,39].  
  Apart from systolic function or EF, LV mass and 
geometry are also related with the emergence of strokes. 
Symptomatic or asymptomatic increased LV mass, known as 
LV hypertrophy (LVH), have proved to be a risk factor for 
cardiovascular morbidity and mortality, including ischemic 
stroke  [40-43]. Increased stroke with LVH risk has been 
shown in all race-ethnicities  [35,40,43-45] and the risk is 
independent of other cardiovascular risk factors, including 
arterial hypertension  [46]. This association between LVH 
and IS has been identified across studies using ECG [41,42], 
echocardiography  [47,48] and MRI  [49]. Some studies have 
demonstrated that patients who fail to reduce LVH are much 
more likely to suffer cardiovascular events, including stroke, 
than those in whom the LV mass is reduced by antihyper-
tensive treatment  [50-54] or physical activity [55]. 
  Moreover, abnormal LV geometry beyond the simple LV 
mass increase has also been associated with an increased risk 
of cardiovascular morbidity. LV geometry may be classified 
into the following four mutually exclusive groups on the 
basis of LV mass and relative wall thickness (RWT): 1) 
concentric hypertrophy (increased mass and increased 
RWT), 2) eccentric hypertrophy (increased mass and normal 
RWT), 3) concentric remodeling (normal mass and increased 
RWT) and 4) normal geometry (normal mass and normal 
RWT). Concentric hypertrophy carries the highest risk, 
followed by eccentric hypertrophy  [56,57]. The role of 
concentric remodeling is more controversial, having con-
ferred cardiovascular risk beyond LV mass in some studies 
but not in others  [58-61].  
  Several studies have assessed the specific risks of LVH 
and LV geometry in the development of IS. In a case-control 
study from the multiethnic NOMASS cohort, LVH was 
associated with a 2.5-fold increase in stroke risk after 
adjustment for other stroke risk factors across all the racial 
and ethnic subgroups. Concentric hypertrophy carried the 
greatest stroke risk, followed by eccentric hypertrophy and 
concentric remodeling  [48]. In the Multi-Ethnic Study of 
Atherosclerosis (MESA)  [49], the relationship of LV mass 
and geometry, measured with cardiac MRI, to incident car-
diovascular events was analyzed in 5,098 participants. 
Increased LV mass-to-volume ratio was independently 
associated with stroke (HR: 4.2 per g/ml, p = 0.005). In 
contrast, LV mass showed the strongest association with 
incident HF events (HR: 1.4 per 10% increment, p < 0.0001). 
The MESA findings point out the importance of LV geo-
metry for the emergence of IS compared to other cardio-
vascular diseases.  
MECHANISMS OF ISCHEMIC STROKE IN HF 
  Under the current TOAST criteria for stroke subtype,   
[37] the mechanism of stroke in patients with HF and low EF 
is classified as cardiogenic embolism if other etiologies are 
ruled out. However, the stroke mechanism in HF may be 
embolism or cerebral hypoperfusion. LV dysfunction causes 
an increased LV end diastolic volume that promotes blood 
stasis in both the LV and left atrium, increasing the chance 
of thrombus formation and the risk of embolic stroke. About 
12% of patients with CM have LV thrombus formation and 
EF is the factor most associated with ventricular thrombus 
formation  [62]. A variety of factors associated with HF 
predispose to thrombosis. These include vascular pathology, 
increased coagulability and impaired flow. Several studies 
have shown that patients with HF have increased plasma 
concentrations of fibrinopeptide A, D-dimer, von Willebrand 
factor, fibrinolytic products, beta-thromboglobulin and endo-
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that predispose to thromboembolic events have been 
associated with the neuroendocrine activation  [64].  
  However, stroke in HF might be also due to cerebral 
hypoperfusion. Patients with low EF have an elevated LV 
filling pressure and a reduced stroke volume, and this causes 
a reduction of systemic blood flow. In patients with adequate 
cerebrovascular reactivity, lowering cerebrovascular resis-
tance through dilatation of the brain arterioles could 
compensate for the reduced cardiac output. Autoregulation 
maintains cerebral blood flow through a wide range of 
systemic blood pressure. Therefore, a reduction in EF should 
not affect cerebral blood flow in a patient with intact 
autoregulation. However, patients with HF may easily 
decompensate hemodynamically and may become hypoten-
sive secondary to cardiac ischemia, arrhythmia or over-
medication with hypotensive drugs. This would limit the 
potential for further dilatation, resulting in the altered 
cerebrovascular reserve capacity observed in patients with 
HF. Increasing severity of HF, indicated by NYHA grade 
and decreasing EF, are correlated with decreased cerebro-
vascular reactivity  [65] and decreased global cerebral blood 
flow  [66].  
  In a case/control study, HF was associated with prior 
stroke/TIA. The risk was higher in patients in the lowest 
tertile of systolic blood pressure (SBP)  [33]. Vulnerability 
of the brain to hypoperfusion in HF is also supported by the 
increased risk of cognitive impairment in HF patients and 
low SBP  [67]. These findings have raised the question 
whether SBP must be reduced to the lowest level tolerated, 
as has been recommended in patients with HF  [33].  
  Embolic and hypoperfusion related strokes differ in their 
localization. Embolic strokes more frequently affect carotid 
than vertebral circulation, due to the different pathways of 
blood supply. In terms of carotid circulation, MCA is more 
affected than ACA. Embolic infarcts are typically medium or 
large size and located in the cortical areas of the brain, 
although subcortical strokes might occur in the case of a 
small embolus that occludes a small perforant artery  [68]. 
Fig. (1) is an example of embolic stroke. 
  In hypoperfusion related ischemia, three types have been 
described as the most frequent  [69]: 
  1. Cortical watershed infarcts (Fig. 2), located at the 
junction of the usual territories of major cerebral arteries in 
free anastomosis (anterior, middle, and posterior cerebral); 2. 
Distal field infarcts, confined to a location at the most distal 
field of supply of an artery that has few or no collaterals, 
such as the upper lateral margin of the lateral ventricle (distal 
field of the lenticulostriate arteries); and 3. Internal border-
zone infarcts, deep infarcts that lie between the territories of 
2 arteries that do not freely anastomose, such as white matter 
infarcts lying between territories supplied by long pene-
trators of the anterior, middle, or posterior cerebral artery. 
  Nevertheless, hypoperfusion and embolism can coexist 
and reduced perfusion may exacerbate ischemia resulting 
from embolism  [70]. In a case-control study, MRI infarct 
volume was measured in a cohort of patients with EF less 
than or equal to 35% with or without concomitant carotid 
stenosis less than 70% and compared with controls with 
normal EF. Patients with reduced EF tended to have larger 
cortical infarcts than patients with normal EF. The mean 
volume of infarcts in patients with high-grade carotid steno-
sis in addition to low EF was greater than in patients with 
low EF, suggesting a hemodynamic interaction between 
arterial stenosis and reduced cardiac output  [69].  
  Nevertheless, the mechanism of stroke in patients with 
HFNEF is not clear. LV hypertrophy might be a marker of 
sub clinical disease that predisposes to other conditions 
directly involved in stroke etiology. Hypertension is well 
recognized as the most frequent antecedent of left ventricular 
hypertrophy in the general population  [71] and is the leading 
risk factor for cerebrovascular disease  [72]. Moreover, LV 
mass correlates with carotid wall thickness and carotid 
plaques  [53,73], which are other important risk factors for 
cerebrovascular disease  [74,75]. Among patients with 
systemic hypertension, arterial structure and function are 
most abnormal when concentric LV hypertrophy is present 
and may contribute to the greater risk for ischemic strokes 
associated with this geometric pattern [49]. 
  Concentric hypertrophy and concentric remodeling have 
been more associated with symptomatic and asymptomatic 
lacunar strokes.  [48, 76], while eccentric hypertrophy is 
more associated with an excess of cardioembolic strokes   
[48]. Lacunar infarcts or small subcortical infarcts result 
from occlusion of a single penetrating artery, usually in 
patients with previous history of hypertension or diabetes. 
Lacunar infarcts show a paradoxical clinical course with a 
favorable prognosis in the short term, with low mortality and 
low disability at hospital discharge but with an increased risk 
of death, stroke recurrence and dementia in the mid and long 
term [77]. Progression of the small vessel disease is believed 
to be caused by arteriolar endothelial dysfunction facilitated 
by hypertension and diabetes, which would increase 
permeability of the brain blood barrier with extravasation of 
toxic substances (mainly proteases), producing neuronal and 
glial damage [78]. Therefore, endothelial dysfunction may be 
the link between vessel thickening and heart remodeling.  
HF AND OUTCOME IN ISCHEMIC STROKE 
  The long-term prognosis for survival free of recurrent 
stroke is important to patients and their caregivers and 
clinicians. Cardioembolic strokes have been associated with 
the most severe acute neurological deficit and the highest 
mortality and worst functional outcome at 90 days [79, 80]. 
In fact, in the EUROSTROKE study  [41], LVH in the ECG 
was associated with an increased risk of fatal stroke, whereas 
risk for non-fatal stroke was non-significant. In addition, 
patients with low EF had more severe strokes as measured 
by National institute of Health Stroke Scale (NIHSS>6) than 
patients with normal EF in the NOMASS study [35].  
  Several community-based studies of stroke and TIA 
prognosis have analyzed the short- and long-term predictors 
of death and disability. Short-term mortality (30-90 days) has 
been related to age, stroke severity, congestive HF, and AF  
[81-84]. For mortality at 1 and 5 years, age, stroke severity 
and congestive HF continue to predict mortality as well as 
onset of ischemic heart disease  [82,85-87].  
  In a community-based study that prospectively included 
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severity (NIHSS6) and mortality at 28 days were associated 
with AF and previous dementia  [88]. The same cohort of 
patients was followed up within 12 months in a later study 
that analyzed the predictors of survival, with dependency 
defined as a modified Rankin Scale (mRS) [89] greater than 
2 and stroke recurrence. Dementia, age, stroke severity and 
AF were associated with death within 1 year. HF was 
independently associated with 1-year dependency (adjusted 
OR: 3.0) but not with survival or stroke recurrence  [90]. 
These findings suggested that patients with HF who have an 
incident stroke have a high risk of early mortality or mid-
term dependency due to the index stroke severity. Never-
theless, HF seems to be also a strong predictor of long-term 
mortality. In a recent study analyzing the predictors of 5-year 
mortality in a large cohort of young patients (age 15 to 49) 
with first-ever IS, HF defined as EF<55% was found to be 
second only to active malignancies at the time of the stroke 
in its association with mortality (adjusted OR: 5.25)  [91]. 
  In most of the previous studies HF has been defined as a 
clinical syndrome without echographic information. Our 
group analyzed the effect of both forms of HF (with low EF 
and HFNEF) on the 90-day outcome in 540 consecutive 
patients with IS from the BASICMAR cohort  [81] studied 
with echocardiogram  [92]. We found an independent asso-
ciation between both forms of HF and poor outcome, defined 
as mRS 3-6 at 90 days, a composite outcome that includes 
dependency and mortality. The adjusted OR was higher for 
HF with low EF (adjusted OR: 3.01, p=0.008) than HFNEF 
(adjusted OR: 2.53, p < 0.001). Initial stroke severity was 
also independently associated with poor outcome, whereas 
thrombolytic treatment and statin pretreatment were 
protective factors. HFNEF patients were older, more fre-
quently women, and less likely to be current smokers than 
patients with low EF. However, there were no differences in 
initial NIHSS neurological severity between HFNEF and HF 
with low EF  [93]. 
  The poor prognosis in cardioembolic stroke is believed to 
be caused by the index stroke because early stroke 
recurrence seems to be low in these patients. Nevertheless, in 
a study of the BASICMAR cohort we analyzed the potential 
risk factors for 7- and 90-day recurrence in patients with 
minor stroke and TIA. We found that HF was independently 
associated with stroke recurrences at 7 days (adjusted OR: 
2.66) and at 90 days (2.41)  [94]. In the NOMASS cohort, 
HF was not independently associated with stroke recurrence 
at 30 days, 1 year or 5 years. However, the recurrent stroke 
rate was notably higher in patients with HF (mean 44%) 
compared with patients without HF (25%)  [95]. 
  The explanation for a worse prognosis, independent of 
EF, in stroke patients with history of HF may be related to 
the main underlying causes such as CAD, hypertension, and 
valvular disease. These patients have a higher atherosclerotic 
burden and endothelial dysfunction, factors proven to be 
associated with higher mortality [96-98]. Moreover, older 
age of patients with prior HF may be a contributory factor, 
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  Most deaths after IS can be directly attributed to the 
initial neurological injury. However, approximately 2-6% of 
all stroke patients die from cardiac causes in the 3 months 
after IS  [99]. After the acute period, cardiac risk declines but 
remains higher than for age-matched controls. The estimated 
annual rate of MI and non-stroke vascular death in stroke 
patients is 2.2% and 2.1%, respectively. The accumulation of 
risk is linear, suggesting that at 10 years after an IS, the risk 
would be 20%  [100]. In a large study conducted to analyze 
the prognostic determinants for cardiac morbidity and 
mortality within 3 months after IS, the most predictive factor 
was history of HF (OR:3.33), followed by diabetes (OR: 
2.11), baseline creatinine (OR:1.77), severe stroke (OR:1.98) 
and long QTc or ventricular extrasystoles on ECG (OR: 
1.93) [101]. As a cause of death in the acute IS population, 
cardiac mortality was second only to neurologic death 
directly resulting from the incident stroke. 
  It is not infrequent that patients with acute strokes show 
an increase in the concentration of cardiac troponin, BNP 
and NT-proBNP  [102,103]. Moreover, patients with higher 
concentration of these biomarkers have a worse prognosis   
[104]. Although there are a number of possible causes of 
myocardial damage and raised troponin after a stroke, the 
mechanism is likely to be the activation of a rennin 
angiotensin aldosterone system (RAAS), which leads to 
vasoconcentration and fluid retention, followed by 
myocardial stress. The myofibrillar necrosis occurs in the 
vicinity of the cardiac nerves, and not in the macrovascular 
distribution seen in patients with CAD  [105]. Neurogenic 
damage is also responsible for cardiac stunning, defined as a 
transient decrease in cardiac function associated with ST and 
Q wave abnormalities and segmental hypokinesis that 
resolves a few days after the onset of the symptoms. It is 
believed to reflect transient coronary vasospasm secondary 
to increased sympathetic tone [106]. Patients with HF and 
chronic neurohormonal activation might have poor adap-
tability following a stroke, with peripheral hypoperfusion 
and more myocardial damage, leading to higher mortality.  
TREATMENT CONSIDERATIONS IN HF PATIENTS 
WITH IS 
  Patients with HF that experienced an IS should be treated 
according to the current guidelines  [107]. Treatment of 
stroke has different phases, including primary prevention, 
acute phase, rehabilitation, and secondary prevention. As 
previously discussed, patients with HF have a high risk of IS. 
Therefore, careful VRF control and optimization of cardiac 
output with maintenance of normal blood pressure and a 
normal heart rate is essential in these patients.  
  Acute phase treatment includes revascularization (phar-
macologic or mechanical thrombolysis, angioplasty) and 
general management. HF patients would benefit from acute 
treatment in a stroke unit, which has proven to lower the risk 
of early neurological deterioration, improve the outcome and 
decrease the length of stay for stroke patients [108].  
  Blood pressure treatment during the acute phase is a 
controversial area in stroke management and different 
clinical trials are ongoing  [109]. Patients with the highest 
and lowest levels of blood pressure in the first 24 hours after 
stroke seem to be more likely to have early neurological 
decline and poorer outcomes; in general, mild hypertension 
is preferred during the first 24h. In patients with HF, blood 
pressure can usually be raised by adequate rehydration with 
saline solutions; patients with low cardiac output may 
occasionally need inotropic support. Rhythm control is also 
essential to optimize cardiac function. 
  Secondary prevention includes strict management of all 
cardiovascular risk factors. In the AHA/ASA guidelines   
[110] for secondary prevention in stroke patients, antihy-
pertensive treatment is recommended for prevention of 
recurrent stroke and other vascular events in persons who 
have had an ischemic stroke or TIA and are beyond the 
hyperacute period (Class I, Level of Evidence A). Normal 
BP levels have been defined as <120/80 mm Hg that coin-
cide with the ACCF/AHA recommendations for HF patients. 
  This is particularly appropriate in patients with HFNEF, 
whose symptoms may respond particularly well to treatments 
that lower blood pressure  [111]. 
  The optimal drug regimen for BP management remains 
uncertain and the choice of specific drugs must be 
individualized by specific patient characteristics. In fact, a 
recent meta-analysis of randomized trials that tested blood 
pressure lowering agents on stroke recurrence in patients 
with stroke/TIA found that all agents that managed to lower 
the blood pressure also reduced recurrent stroke and 
cardiovascular events  [112]. 
  Therefore, drugs that can both control BP and treat HF 
should be preferred. This includes the use of diuretics, 
ACEIs, and beta blockers. However, some antihypertensive 
agents should be avoided in patients with HF because of 
their ability to depress cardiac function, such as most 
calcium channel blockers, or lead to salt and water retention, 
such as minoxidil.  
  Increased sympathetic activity has been found after acute 
stroke and is associated with poor neurological prognosis. 
Beta-blocker use has been associated with less severe strokes 
on presentation and may be cerebroprotective due to a 
sympatholytic effect and inhibition of thrombin generation, 
modulation of blood glucose and reduction of acute 
inflammation  [113]. Therefore, use of one of the beta-
blockers proven to reduce mortality (bisoprolol, carvedilol 
and sustained release metoprolol succinate) is recommended 
for IS patients with stable HF  [1]. 
  HF has been associated with resistance to the actions of 
insulin  [114] and the resulting hyperinsulinemia may 
promote both cardiac and vascular hypertrophy, hastening 
the progression of HF  [115]. Moreover, diabetes mellitus is 
a risk factor for stroke recurrence  [116] and strict diabetes 
control is mandatory in these patients. 
  The drugs routinely used in the management of HF in 
nondiabetic patients are also administered to those with dia-
betes mellitus. ACEI and beta-blockers prevent the pro-
gression of HF in diabetic and non diabetic patients. How-
ever, thiazolidinediones have been associated with increased 
peripheral edema and symptomatic HF and these oral 
antidiabetic agents should be used with caution in diabetic 
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  AF might worsen HF symptoms and increase the risk of 
thromboembolic events by several mechanisms, including 
compromising cardiac output, decreasing coronary perfusion 
and aggravating cardiac contraction and relaxation. Control 
of ventricular rate and prevention of thromboembolic events 
are essential elements of treatment in patients with HF and 
AF. However, rhythm control has not been found to be more 
effective in preventing cardiovascular deaths or embolic 
events including strokes compared with rate control strategy 
in patients with HF and AF  [20]. The rate-control therapy 
reduces rates of hospitalization and need for repeated 
cardioversion and is recommended in these patients.  
Antithrombotic Therapy 
  In general, patients with cardiac disease and cerebral 
infarction face a high risk of recurrent stroke. Because it is 
often difficult to determine the precise mechanism, the 
choice of a platelet inhibitor or anticoagulant drug may be 
difficult. Moreover, trials studying the stroke risk or 
response to anticoagulation have included patients with CM, 
low EF and HF interchangeably  [117]. 
  In the AHA/ASA Guidelines  [110] for secondary 
prevention of stroke, recommendations for medical treatment 
in patients with cardiogenic embolism include the following:  
  For patients with ischemic stroke or TIA who have 
dilated CM, either warfarin (INR 2.0-3.0) or antiplatelet 
therapy may be considered for prevention of recurrent events 
(Class IIb, Level of Evidence C). Potential antiplatelet 
therapies used to prevent recurrent stroke include aspirin 
(50-325 mg/d), the combination of aspirin (25 mg twice 
daily) and extended release dipyridamole (200 mg twice 
daily), and clopidogrel (75 mg daily). However, IS in 
patients with HF due to AF, acute MI with LV thrombus, 
rheumatic mitral valve disease or prosthetic heart valves 
should be treated with oral anticoagulants.  
  Nevertheless, there is no clear indication of anticoagu-
lation in patients with HF, without valvular disease, that are 
in sinus rhythm. The current guidelines from the AHA/ACC  
[118] do not support the routine use of warfarin in patients 
with dilated CM. In the European Stroke Initiative 
recommendations for stroke management  [107], there is no 
specific recommendation for primary or secondary stroke 
prevention in patients with cardiomyopathy who are at sinus 
rhythm. There are also no data on whether anticoagulation is 
beneficial in patients with HFNEF.  
  In the SAVE study, both warfarin and aspirin (given 
separately) were associated with a lower risk for stroke than 
no antithrombotic therapy  [24]. Other large studies of MI 
patients have compared the effect of warfarin and aspirin in 
the prevention of new vascular events. Results from these 
trials show that warfarin, at moderate or high dose (INR 2.8 
to 4.8), in combination with aspirin or given alone, is 
superior to aspirin alone in reducing the incidence of 
composite events after an acute MI but is associated with a 
higher risk of bleeding. However, warfarin at low dose (INR 
<2) plus aspirin is not superior to aspirin (80mg) alone   
[119]. 
  Warfarin appears to exert a similar effect on the reduc-
tion of stroke both in patients with nonischemic CM and in 
those with ischemic heart disease  [38]. Therefore, warfarin 
is prescribed to prevent cardioembolic events in patients with 
CM, although no randomized clinical studies have demons-
trated the efficacy of anticoagulation. Several trials have 
been initiated to address this issue. 
  The Warfarin and Antiplatelet Therapy in Chronic Heart 
Failure Trial (WATCH)  [120] was designed to evaluate the 
efficacy of antithrombotic strategies among symptomatic HF 
patients in sinus rhythm with EF  35%. Patients were 
randomized to open-label warfarin (target INR 2.5 -3.0) or 
double-blind antiplatelet therapy with aspirin (162 mg) or 
clopidogrel (75 mg). The trial was terminated early for poor 
recruitment after 1587 patients of the 4500 planned were 
enrolled, with a resulting reduction of its power to achieve its 
original objective. The primary outcome was the time to first 
occurrence of death, nonfatal myocardial infarction, or 
nonfatal stroke. For the primary composite endpoint, the 
hazard ratios were as follows: for warfarin vs. aspirin, 0.98 
,p=0.77; for clopidogrel vs. aspirin, 1.08, p=0.57; and for 
warfarin vs. clopidogrel, 0.89, p=0.39. However, warfarin 
was associated with fewer nonfatal strokes than aspirin or 
clopidogrel.  
  The ongoing Warfarin Versus Aspirin for Reduced 
Cardiac Ejection Fraction (WARCEF) study  [121] is 
comparing primary endpoint (time to first occurrence of IS, 
intracerebral hemorrhage or death) between warfarin (INR 
2.5-3) and aspirin (325 mg) in patients in all NYHA classes 
(I-IV) with low EF ( 35%) who are at sinus rhythm. The 
target enrollment is 3201 patients. This trial is not statis-
tically powerful enough to determine whether warfarin has 
an effect on ischemic stroke risk reduction; however, by 
pooling results with those of other trials, we may be able to 
draw some conclusions about this issue.  
CONCLUSIONS 
  Heart failure is a growing health problem due in part to 
population aging. Heart failure and stroke share similar risk 
factors and heart failure is associated with higher risk of IS, 
especially in patients with low EF. The stroke mechanisms 
include embolism and hypoperfusion. Stroke in HF is 
associated with more severity, recurrence risk and early- and 
long-term mortality regardless of EF. Current studies on new 
acute phase treatments and secondary prevention have the 
potential to improve the prognosis. 
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